These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 7756648)
1. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Kotzé HF; Lamprecht S; Badenhorst PN Blood; 1995 Jun; 85(11):3158-63. PubMed ID: 7756648 [TBL] [Abstract][Full Text] [Related]
2. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733 [TBL] [Abstract][Full Text] [Related]
3. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons. Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323 [TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition. Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274 [TBL] [Abstract][Full Text] [Related]
5. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009 [TBL] [Abstract][Full Text] [Related]
6. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787 [TBL] [Abstract][Full Text] [Related]
7. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin. Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304 [TBL] [Abstract][Full Text] [Related]
8. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089 [TBL] [Abstract][Full Text] [Related]
9. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Kotzé HF; Lamprecht S; Badenhorst PN; Roodt JP; van Wyk V Thromb Haemost; 1997 Jun; 77(6):1137-42. PubMed ID: 9241746 [TBL] [Abstract][Full Text] [Related]
10. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336 [TBL] [Abstract][Full Text] [Related]
11. PLATSAK, a potent antithrombotic and fibrinolytic protein, inhibits arterial and venous thrombosis in a baboon model. van Zyl WB; Pretorius GH; Lamprecht S; Roodt JP; Kotzé HF Thromb Res; 2000 Jun; 98(5):435-43. PubMed ID: 10828483 [TBL] [Abstract][Full Text] [Related]
12. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Schaffer LW; Davidson JT; Vlasuk GP; Siegl PK Circulation; 1991 Oct; 84(4):1741-8. PubMed ID: 1833089 [TBL] [Abstract][Full Text] [Related]
14. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist. Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban. Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001 [TBL] [Abstract][Full Text] [Related]
16. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model. Krupinski K; Breddin HK Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199 [TBL] [Abstract][Full Text] [Related]
17. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Heras M; Chesebro JH; Webster MW; Mruk JS; Grill DE; Penny WJ; Bowie EJ; Badimon L; Fuster V Circulation; 1990 Oct; 82(4):1476-84. PubMed ID: 2401076 [TBL] [Abstract][Full Text] [Related]
18. The effects of recombinant desulphatohirudin on arterial thrombosis in rats. Talbot MD; Ambler J; Butler KD; Lees CM; Mitchell KA; Peters RF; Tweed MF; Wallis RB Haemostasis; 1991; 21 Suppl 1():73-9. PubMed ID: 1654294 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867 [TBL] [Abstract][Full Text] [Related]
20. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Lumsden AB; Kelly AB; Schneider PA; Krupski WC; Dodson T; Hanson SR; Harker LA Blood; 1993 Apr; 81(7):1762-70. PubMed ID: 8461462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]